AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26511934 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller left-sided DLTs
Number of subjects: 1135
Study 26512574 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Vincristine, and Cisplatin (GVP) regimen
Number of subjects: 26
Study 26512596 — intervention group
Group type: EXPERIMENTAL
Intervention: CMRLAX
Number of subjects: 100
Study 26512596 — intervention group
Group type: COMPARATOR
Intervention: CMRSAX
Number of subjects: 100
Study 26512596 — intervention group
Group type: COMPARATOR
Intervention: TTE
Number of subjects: 100
Study 26512876 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous afatinib 30 mg plus nintedanib 150 mg
Number of subjects: 70
Study 26512876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent afatinib 40 mg plus nintedanib 150 mg
Number of subjects: 70
Study 26512876 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous afatinib plus nintedanib at MTD
Number of subjects: 70
Study 26513619 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) imaging of the terminal ileum, with increased epithelial gap density observed in normal appearing mucosa.
Number of subjects: 24
Study 26514176 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FIMX
Number of subjects: 12
Study 26514251 — intervention group
Group type: EXPERIMENTAL
Intervention: RECO stent retriever
Number of subjects: 0
Study 26514315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg BID co-administered with digoxin 0.25 mg once daily on days 9 to 15
Number of subjects: 0
Study 26514315 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.25 mg BID on day 1 and 0.25 mg once daily on days 2 to 8
Number of subjects: 0
Study 26514334 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic artery embolization (SAE)
Number of subjects: 109
Study 26514334 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 109
Study 26514334 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (splenectomy and SAE)
Number of subjects: 109
Study 26514420 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine alone (10 μg dLPS)
Number of subjects: 20
Study 26514420 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine plus CPG 7909 (250 or 500 μg)
Number of subjects: 20
Study 26514928 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral support techniques (preparation, distraction, coaching, reinforcement) during in-office tympanostomy tube placement
Number of subjects: 70
Study 26514928 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis system for delivering local anesthesia and integrated tube delivery system
Number of subjects: 70
Study 26514928 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based local anesthesia and tube delivery with behavioral techniques
Number of subjects: 70
Study 26515198 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (r-tPA) treatment
Number of subjects: 106
Study 26515198 — intervention group
Group type: EXPERIMENTAL
Intervention: Information presentation strategies for r-tPA
Number of subjects: 106
Study 26515198 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-benefit communication regarding r-tPA
Number of subjects: 106
Study 26515198 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making tool for r-tPA
Number of subjects: 106
Study 26515246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower trunk accelerations during a six-minute walk test
Number of subjects: 29
Study 26515246 — intervention group
Group type: EXPERIMENTAL
Intervention: One inertial sensor on the lower trunk
Number of subjects: 29
Study 26515457 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily Basal Insulin (BI) therapy in the morning
Number of subjects: 0
Study 26515457 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily Basal Insulin (BI) therapy
Number of subjects: 0
Study 26515457 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline A1c, postprandial glucose (PPG), difference between PPG and fasting plasma glucose, duration of diabetes
Number of subjects: 0
Study 26516010 — intervention group
Group type: EXPERIMENTAL
Intervention: APOC3 Loss-of-Function Mutations
Number of subjects: 0
Study 26516010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APOC3 mutations)
Number of subjects: 0
Study 26516584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000-500 mg) as a single infusion or multiple intravenous infusions over 11 days
Number of subjects: 0
Study 26516584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime, avibactam, or ceftazidime-avibactam over 4 days
Number of subjects: 0
Study 26516584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000-500 mg), metronidazole (500 mg), or metronidazole followed by ceftazidime-avibactam over 4 days
Number of subjects: 0
Study 26516584 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple doses of ceftazidime, avibactam, and metronidazole
Number of subjects: 0
Study 26518132 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day treatment (T14) with chloroquine (CQ) for 3 days (10, 10, and 5 mg/kg) and primaquine (PQ) daily for 14 days (0.25 mg/kg)
Number of subjects: 153
Study 26518132 — intervention group
Group type: COMPARATOR
Intervention: Intermittent single dose (ISD) regimen with a single dose of CQ (10 mg/kg) and PQ (0.75 mg/kg) on days 0, 30, 60, 180, 210, and 240
Number of subjects: 153
Study 26518132 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day treatment (T14)
Number of subjects: 153
Study 26518379 — intervention group
Group type: EXPERIMENTAL
Intervention: Collis-Nissen procedure
Number of subjects: 130
Study 26518379 — intervention group
Group type: COMPARATOR
Intervention: Nissen procedure
Number of subjects: 130
Study 26518736 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-word test
Number of subjects: 585
Study 26518736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three neuropsychological tests (five-word, cognitive disorders examination, verbal fluency)
Number of subjects: 585
Study 26518736 — intervention group
Group type: COMPARATOR
Intervention: Cognitively healthy individuals (CHI)
Number of subjects: 585
Study 26518736 — intervention group
Group type: COMPARATOR
Intervention: Mild cognitive impairment or demented individuals (MCI-DI)
Number of subjects: 585
Study 26518979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy at an initial dose of 0.3 mg/kg/day for 2 weeks, followed by 0.6 mg/kg/day for an additional 2 weeks, then increased by 0.6 mg/kg/day up to a maximum of 10.2 mg/kg/day or 400 mg/day until seizure free confirmed by HV-EEG.
Number of subjects: 20
Study 26518979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy during the 12-week maintenance phase.
Number of subjects: 20
Study 26518979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy.
Number of subjects: 20
Study 26519231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 150 mg
Number of subjects: 56
Study 26520062 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortness of Breath with Daily Activities (SOBDA) questionnaire
Number of subjects: 4967
Study 26520062 — intervention group
Group type: COMPARATOR
Intervention: Responders (defined by TDI, SGRQ, CAT, and trough FEV1 levels)
Number of subjects: 4967
Study 26521238 — intervention group
Group type: EXPERIMENTAL
Intervention: Geary Hinkley model for tumor volume measurement
Number of subjects: 0
Study 26521268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and Sofosbuvir (SOF) for 12 weeks
Number of subjects: 34
Study 26522260 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 26
Study 26523388 — intervention group
Group type: EXPERIMENTAL
Intervention: Flood-illuminated adaptive optics (FIAO) imaging of the retinal periphery
Number of subjects: 50
Study 26523388 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifting the entry pupil toward the optical axis
Number of subjects: 50
Study 26523388 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 50
Study 26523525 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (4 g of eicosapentaenoic acid and docosahexaenoic acid daily)
Number of subjects: 27
Study 26523525 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation
Number of subjects: 27
Study 26523525 — intervention group
Group type: COMPARATOR
Intervention: Control group (obese women)
Number of subjects: 27
Study 26525052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion at a dose of 0.2-1.4 μg/kg/h with symptom-triggered benzodiazepine (10 mg diazepam bolus) as needed
Number of subjects: 72
Study 26525052 — intervention group
Group type: COMPARATOR
Intervention: Symptom-triggered 10 mg boluses of diazepam only
Number of subjects: 72
Study 26525461 — intervention group
Group type: EXPERIMENTAL
Intervention: JASPER parent-mediated intervention
Number of subjects: 86
Study 26525461 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 86
Study 26525461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirrored pacing strategy
Number of subjects: 86
Study 26525557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HAART
Number of subjects: 3022
Study 26525557 — intervention group
Group type: COMPARATOR
Intervention: HAART naïve mothers (CD4 < 250)
Number of subjects: 3022
Study 26525557 — intervention group
Group type: COMPARATOR
Intervention: HAART ineligible mothers
Number of subjects: 3022
Study 26526622 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute-on-chronic disease (AoC)
Number of subjects: 103363
Study 26526622 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury (AKI)
Number of subjects: 103363
Study 26526622 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 103363
Study 26526622 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 103363
Study 26526622 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated admission serum potassium
Number of subjects: 103363
Study 26526721 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133+ autologous stem cells administered intramuscularly
Number of subjects: 8
Study 26526971 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (up to 400 mg)
Number of subjects: 499
Study 26526984 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib (80 mg, Cohort-1)
Number of subjects: 12
Study 26526984 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib (150 mg, Cohort-2)
Number of subjects: 12
Study 26527676 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-reported response
Number of subjects: 575
Study 26527676 — intervention group
Group type: EXPERIMENTAL
Intervention: 2014 NIH-calculated response
Number of subjects: 575
Study 26527676 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in the 2005 NIH clinician-reported skin score
Number of subjects: 575
Study 26527676 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in the 0 to 10 patient-reported itching score
Number of subjects: 575
Study 26527676 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in the Lee skin symptom score
Number of subjects: 575
Study 26527676 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant score
Number of subjects: 575
Study 26527780 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning HSCT
Number of subjects: 114
Study 26528500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual focus narrow band imaging (dNBI)
Number of subjects: 26
Study 26528500 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 26
Study 26528503 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire biliary cannulation (GWC)
Number of subjects: 320
Study 26528503 — intervention group
Group type: COMPARATOR
Intervention: Standard contrast-assisted cannulation (CC)
Number of subjects: 320
Study 26528879 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measured on 3rd postoperative day (POD)
Number of subjects: 504
Study 26528879 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measured on 5th postoperative day (POD)
Number of subjects: 504
Study 26528879 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) and C-reactive protein (CRP) measured together on 5th postoperative day (POD)
Number of subjects: 504
Study 26528879 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measured on 3rd postoperative day (POD)
Number of subjects: 504
Study 26528879 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measured on 5th postoperative day (POD)
Number of subjects: 504
Study 26528879 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood count (WBC) measured on 3rd postoperative day (POD)
Number of subjects: 504
Study 26528879 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood count (WBC) measured on 5th postoperative day (POD)
Number of subjects: 504
Study 26529118 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 47
Study 26529118 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 47
Study 26529118 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 30 mg
Number of subjects: 47
Study 26529118 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline 100 mg
Number of subjects: 47
Study 26529238 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of AERAS-402 followed by MVA85A
Number of subjects: 40
Study 26529238 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of AERAS-402
Number of subjects: 40
Study 26529238 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402 followed by MVA85A
Number of subjects: 40
Study 26529255 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour fasting
Number of subjects: 19
Study 26529255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (sirtuin activator)
Number of subjects: 19
Study 26529255 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT3 activation (genetic and pharmacologic)
Number of subjects: 19
Study 26529255 — intervention group
Group type: COMPARATOR
Intervention: Control (refed individuals)
Number of subjects: 19
Study 26529370 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive interval debulking surgery (MI-IDS)
Number of subjects: 52
Study 26529569 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0
Study 26529569 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 26529569 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX Score II
Number of subjects: 0
Study 26529632 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa treatment (1 mg/kg six times per week or 2 mg/kg thrice weekly)
Number of subjects: 37
Study 26529632 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa treatment
Number of subjects: 37
Study 26530031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard homework
Number of subjects: 12
Study 26530031 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified (picture-based) homework
Number of subjects: 12
Study 26530031 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminders
Number of subjects: 12
Study 26530031 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified homework
Number of subjects: 12
Study 26530268 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1299
Study 26530268 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg
Number of subjects: 1299
Study 26530268 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1299
Study 26531748 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard primary treatment according to the stage of disease
Number of subjects: 700
Study 26535053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure for 10 days
Number of subjects: 78
Study 26535053 — intervention group
Group type: COMPARATOR
Intervention: Sham group (light pressure on non-acupoints for 10 days)
Number of subjects: 78
Study 26535123 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 580
Study 26535126 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 240
Study 26535126 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 240
Study 26535126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 26535126 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (both doses)
Number of subjects: 240
Study 26535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every 4 weeks (120/Q4W)
Number of subjects: 456
Study 26535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 90 mg every 2 weeks (90/Q2W)
Number of subjects: 456
Study 26535134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 26535135 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg plus Methotrexate (MTX) for 52 weeks
Number of subjects: 196
Study 26535135 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (DAS28 ≤3.2) at week 13
Number of subjects: 196
Study 26535135 — intervention group
Group type: COMPARATOR
Intervention: Non-responders (DAS28 >3.2) at week 13
Number of subjects: 196
Study 26535146 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release (DR) prednisone 5 mg once daily for 12 weeks
Number of subjects: 350
Study 26535146 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 350
Study 26535512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus Rituximab
Number of subjects: 38
Study 26536156 — intervention group
Group type: EXPERIMENTAL
Intervention: TranQuill Sling Snoreplasty (TSS)
Number of subjects: 20
Study 26536198 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1
Study 26536893 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin treatment
Number of subjects: 8
Study 26537529 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day
Number of subjects: 286
Study 26537623 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (starting dose of 1 μg/kg)
Number of subjects: 24
Study 26537623 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (after discontinuation)
Number of subjects: 24
Study 26537623 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (during treatment)
Number of subjects: 24
Study 26537851 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow derived MSCs, 1.5 × 10(6) per kg body weight, administered intravenously at 25 and 26 weeks after transplantation.
Number of subjects: 10
Study 26538309 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line microfilters
Number of subjects: 504
Study 26538309 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 504
Study 26538477 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (BWLI)
Number of subjects: 470
Study 26539981 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1 g at D0, D15, and M6)
Number of subjects: 12
Study 26540234 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BSM mass in nonsevere asthma
Number of subjects: 34
Study 26540234 — intervention group
Group type: EXPERIMENTAL
Intervention: High BSM
Number of subjects: 34
Study 26540612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-Disordered Breathing (SDB) in patients with CMS
Number of subjects: 23
Study 26540612 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 23
Study 26540612 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Patent Foramen Ovale (PFO) in subjects with SDB
Number of subjects: 23
Study 26540612 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of AHI with systemic blood pressure
Number of subjects: 23
Study 26540612 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of AHI with pulmonary artery pressure
Number of subjects: 23
Study 26541344 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake quartile 2 (3.0 ± 0.7 kcal/kg/day)
Number of subjects: 1004
Study 26541344 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake quartile 1 (0.5 ± 0.6 kcal/kg/day)
Number of subjects: 1004
Study 26541344 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake quartiles 1 and 2
Number of subjects: 1004
Study 26541392 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HFM)
Number of subjects: 17
Study 26541511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg, up to four cycles, administered in 3 week intervals)
Number of subjects: 103
Study 26541586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (IMMU-132)
Number of subjects: 6
Study 26542025 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared reporting (patients self-reported toxicities and performance status viewed by clinicians)
Number of subjects: 44
Study 26542025 — intervention group
Group type: COMPARATOR
Intervention: Non-shared reporting (patients self-reported toxicities but reports not shared with clinicians)
Number of subjects: 44
Study 26542280 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat (LCI699)
Number of subjects: 19
Study 26542378 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO/GS-4059 (20 mg to 600 mg once daily, with twice-daily regimens of 240 mg and 300 mg)
Number of subjects: 90
Study 26542378 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO/GS-4059
Number of subjects: 90
Study 26542493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 7500
Study 26542493 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider surveys
Number of subjects: 7500
Study 26542493 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart abstraction and core laboratory lipid levels
Number of subjects: 7500